Shield Therapeutics plc (LON:STX - Get Free Report) was up 11.7% during trading on Wednesday . The stock traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.14 ($0.07). Approximately 4,623,609 shares traded hands during trading, an increase of 120% from the average daily volume of 2,102,008 shares. The stock had previously closed at GBX 4.60 ($0.06).
Shield Therapeutics Stock Up 1.2%
The firm's 50-day moving average is GBX 3.56 and its 200 day moving average is GBX 3.10. The firm has a market capitalization of £55.40 million, a PE ratio of -1.45 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05.
Shield Therapeutics Company Profile
(
Get Free Report)
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Further Reading
Before you consider Shield Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.
While Shield Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
